LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.

    Sarzani, Riccardo / Giulietti, Federico / Pentima, Chiara Di / Giordano, Piero / Spannella, Francesco

    European journal of preventive cardiology

    2021  Volume 28, Issue 16, Page(s) e10–e13

    MeSH term(s) Humans ; Angiotensin-Converting Enzyme Inhibitors ; Angiotensin II Type 1 Receptor Blockers ; COVID-19 ; Angiotensin-Converting Enzyme 2 ; Renin-Angiotensin System
    Chemical Substances Angiotensin-Converting Enzyme Inhibitors ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Language English
    Publishing date 2021-02-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2626011-6
    ISSN 2047-4881 ; 2047-4873
    ISSN (online) 2047-4881
    ISSN 2047-4873
    DOI 10.1177/2047487320918421
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4686: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers

    Sarzani, Riccardo / Giulietti, Federico / Pentima, Chiara Di / Giordano, Piero / Spannella, Francesco

    Eur J Prev Cardiol

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #60334
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.

    Matsuzawa, Yasushi / Ogawa, Hisao / Kimura, Kazuo / Konishi, Masaaki / Kirigaya, Jin / Fukui, Kazuki / Tsukahara, Kengo / Shimizu, Hiroyuki / Iwabuchi, Keisuke / Yamada, Yu / Saka, Kenichiro / Takeuchi, Ichiro / Hirano, Toshio / Tamura, Kouichi

    Hypertension research : official journal of the Japanese Society of Hypertension

    2020  Volume 43, Issue 11, Page(s) 1257–1266

    Abstract: ... patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 ... severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture ... receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 ...

    Abstract Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak initiated on the Diamond Princess Cruise Ship at Yokohama harbor in February 2020, we have been doing our best to treat COVID-19 patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 (ACE2), and they may inhibit the worsening of pathological conditions. We aimed to examine whether preceding use of ACEIs and ARBs affected the clinical manifestations and prognosis of COVID-19 patients. One hundred fifty-one consecutive patients (mean age 60 ± 19 years) with polymerase-chain-reaction proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture, Japan, were analyzed in this multicenter retrospective observational study. Among all COVID-19 patients, in the multiple regression analysis, older age (age ≥ 65 years) was significantly associated with the primary composite outcome (odds ratio (OR) 6.63, 95% confidence interval (CI) 2.28-22.78, P < 0.001), which consisted of (i) in-hospital death, (ii) extracorporeal membrane oxygenation, (iii) mechanical ventilation, including invasive and noninvasive methods, and (iv) admission to the intensive care unit. In COVID-19 patients with hypertension, preceding ACEI/ARB use was significantly associated with a lower occurrence of new-onset or worsening mental confusion (OR 0.06, 95% CI 0.002-0.69, P = 0.02), which was defined by the confusion criterion, which included mild disorientation or hallucination with an estimation of medical history of mental status, after adjustment for age, sex, and diabetes. In conclusion, older age was a significant contributor to a worse prognosis in COVID-19 patients, and ACEIs/ARBs could be beneficial for the prevention of confusion in COVID-19 patients with hypertension.
    MeSH term(s) Adult ; Age Factors ; Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Betacoronavirus ; COVID-19 ; Confusion/prevention & control ; Coronavirus Infections/mortality ; Coronavirus Infections/psychology ; Coronavirus Infections/therapy ; Female ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/mortality ; Pneumonia, Viral/psychology ; Pneumonia, Viral/therapy ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index
    Chemical Substances Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors
    Keywords covid19
    Language English
    Publishing date 2020-08-21
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1175297-x
    ISSN 1348-4214 ; 0916-9636
    ISSN (online) 1348-4214
    ISSN 0916-9636
    DOI 10.1038/s41440-020-00535-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3898: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease

    Guo, Junyi / Huang, Zheng / Lin, Li / Lv, Jiagao

    Journal of the American Heart Association, 9(7):e016219

    A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

    2020  

    Abstract: ... effect to inhibit angiotensin‐converting enzyme 1 (ACE1) or block angiotensin II type 1 receptor.6, 7, 8 ... with coronary heart disease.3, 4, 5 Angiotensin‐converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are ... that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) uses severe acute respiratory syndrome coronavirus (SARS‐CoV ...

    Abstract The prevalence of coronavirus disease 2019 (COVID‐19) has posed a great threat to people's health worldwide, bringing a great challenges to the public healthcare systems. A recent study has confirmed that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) uses severe acute respiratory syndrome coronavirus (SARS‐CoV) receptor angiotensin‐converting enzyme 2 (ACE2) for host cell entry.1 ACE2 expression was previously found to correlate with susceptibility to SARS‐CoV infection in vitro.2 As with SARS‐CoV, higher ACE2 expression might also lead to higher risk of SARS‐CoV‐2 infection. See Article by Sommerstein et al. According to available clinical data, ≈15% to 30% of the COVID‐19 patients are with hypertension and ≈2.5% to 15% are with coronary heart disease.3, 4, 5 Angiotensin‐converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are widely used in the treatment of these cardiovascular diseases. Interestingly, several studies have shown that ACEIs/ARBs exhibit ability to upregulate ACE2 expression in addition to their main pharmacological effect to inhibit angiotensin‐converting enzyme 1 (ACE1) or block angiotensin II type 1 receptor.6, 7, 8 Considering that ACE2 expression might correlate with the susceptibility to SARS‐CoV‐2, intake of ACEIs/ARBs might predispose patients to the infection of SARS‐CoV‐2. Therefore, some cardiologists suggested that patients should discontinue ACEIs/ARBs to avoid the potential increased risk of SARS‐CoV‐2 infection.9 However, there is evidence demonstrating that the activation of the renin‐angiotensin system (RAS) and the downregulation of ACE2 expression are involved in the pathological process of lung injury after SARS‐CoV infection.10 Recently, it has been reported that serum level of angiotensin II is significantly elevated in COVID‐19 patients and exhibits a linear positive correlation to viral load and lung injury.11 Activation of the RAS can cause widespread endothelial dysfunction and varying degrees of multiple organ (heart, kidney, and lung) injuries. Thus, intake of ACEIs/ARBs might probably relieve the lung injury and absolutely decrease heart and renal damage resulting from the RAS activation. These possibilities pose a dilemma for the cardiologists in terms of recommending whether to discontinue ACEIs/ARBs or not. On the basis of the current literature, a viewpoint on the potential influence of ACEIs/ARBs on the onset and severity of SARS‐CoV‐2 infection is proposed in this article
    Keywords COVID-19 ; ACEI/ARB ; angiotensin‐converting enzyme 2 ; cardiovascular disease ; SARS‐CoV‐2 ; covid19
    Language English
    Publishing country de
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study

    Matsuzawa, Yasushi / Ogawa, Hisao / Kimura, Kazuo / Konishi, Masaaki / Kirigaya, Jin / Fukui, Kazuki / Tsukahara, Kengo / Shimizu, Hiroyuki / Iwabuchi, Keisuke / Yamada, Yu / Saka, Kenichiro / Takeuchi, Ichiro / Hirano, Toshio / Tamura, Kouichi

    Hypertens Res

    Abstract: ... patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 ... severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture ... receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 ...

    Abstract Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak initiated on the Diamond Princess Cruise Ship at Yokohama harbor in February 2020, we have been doing our best to treat COVID-19 patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 (ACE2), and they may inhibit the worsening of pathological conditions. We aimed to examine whether preceding use of ACEIs and ARBs affected the clinical manifestations and prognosis of COVID-19 patients. One hundred fifty-one consecutive patients (mean age 60 ± 19 years) with polymerase-chain-reaction proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture, Japan, were analyzed in this multicenter retrospective observational study. Among all COVID-19 patients, in the multiple regression analysis, older age (age ≥ 65 years) was significantly associated with the primary composite outcome (odds ratio (OR) 6.63, 95% confidence interval (CI) 2.28-22.78, P < 0.001), which consisted of (i) in-hospital death, (ii) extracorporeal membrane oxygenation, (iii) mechanical ventilation, including invasive and noninvasive methods, and (iv) admission to the intensive care unit. In COVID-19 patients with hypertension, preceding ACEI/ARB use was significantly associated with a lower occurrence of new-onset or worsening mental confusion (OR 0.06, 95% CI 0.002-0.69, P = 0.02), which was defined by the confusion criterion, which included mild disorientation or hallucination with an estimation of medical history of mental status, after adjustment for age, sex, and diabetes. In conclusion, older age was a significant contributor to a worse prognosis in COVID-19 patients, and ACEIs/ARBs could be beneficial for the prevention of confusion in COVID-19 patients with hypertension.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #725057
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan

    Matsuzawa Yasushi / Ogawa Hisao / Kimura Kazuo / Konishi Masaaki / Kirigaya Jin / Fukui Kazuki / Tsukahara Kengo / Shimizu Hiroyuki / Iwabuchi Keisuke / Yamada Yu / Saka Kenichiro / Takeuchi Ichiro / Hirano Toshio / Tamura Kouichi

    https://www.nature.com/articles/s41440-020-00535-8

    a retrospective cohort study.

    2020  

    Abstract: ... patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 ... severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture ... receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 ...

    Abstract Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak initiated on the Diamond Princess Cruise Ship at Yokohama harbor in February 2020, we have been doing our best to treat COVID-19 patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 (ACE2), and they may inhibit the worsening of pathological conditions. We aimed to examine whether preceding use of ACEIs and ARBs affected the clinical manifestations and prognosis of COVID-19 patients. One hundred fifty-one consecutive patients (mean age 60 ± 19 years) with polymerase-chain-reaction proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture, Japan, were analyzed in this multicenter retrospective observational study. Among all COVID-19 patients, in the multiple regression analysis, older age (age ≥ 65 years) was significantly associated with the primary composite outcome (odds ratio (OR) 6.63, 95% confidence interval (CI) 2.28-22.78, P < 0.001), which consisted of (i) in-hospital death, (ii) extracorporeal membrane oxygenation, (iii) mechanical ventilation, including invasive and noninvasive methods, and (iv) admission to the intensive care unit. In COVID-19 patients with hypertension, preceding ACEI/ARB use was significantly associated with a lower occurrence of new-onset or worsening mental confusion (OR 0.06, 95% CI 0.002-0.69, P = 0.02), which was defined by the confusion criterion, which included mild disorientation or hallucination with an estimation of medical history of mental status, after adjustment for age, sex, and diabetes. In conclusion, older age was a significant contributor to a worse prognosis in COVID-19 patients, and ACEIs/ARBs could be beneficial for the prevention of confusion in COVID-19 patients with hypertension.
    Keywords covid19
    Subject code 610
    Language English
    Publisher Nature Publishing Group
    Publishing country jp
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

    Lin, Li

    Journal of the American Heart Association, 9(7):e016219

    2020  

    Abstract: ... effect to inhibit angiotensin‐converting enzyme 1 (ACE1) or block angiotensin II type 1 receptor.6, 7, 8 ... with coronary heart disease.3, 4, 5 Angiotensin‐converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are ... that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) uses severe acute respiratory syndrome coronavirus (SARS‐CoV ...

    Abstract The prevalence of coronavirus disease 2019 (COVID‐19) has posed a great threat to people's health worldwide, bringing a great challenges to the public healthcare systems. A recent study has confirmed that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) uses severe acute respiratory syndrome coronavirus (SARS‐CoV) receptor angiotensin‐converting enzyme 2 (ACE2) for host cell entry.1 ACE2 expression was previously found to correlate with susceptibility to SARS‐CoV infection in vitro.2 As with SARS‐CoV, higher ACE2 expression might also lead to higher risk of SARS‐CoV‐2 infection. See Article by Sommerstein et al. According to available clinical data, ≈15% to 30% of the COVID‐19 patients are with hypertension and ≈2.5% to 15% are with coronary heart disease.3, 4, 5 Angiotensin‐converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are widely used in the treatment of these cardiovascular diseases. Interestingly, several studies have shown that ACEIs/ARBs exhibit ability to upregulate ACE2 expression in addition to their main pharmacological effect to inhibit angiotensin‐converting enzyme 1 (ACE1) or block angiotensin II type 1 receptor.6, 7, 8 Considering that ACE2 expression might correlate with the susceptibility to SARS‐CoV‐2, intake of ACEIs/ARBs might predispose patients to the infection of SARS‐CoV‐2. Therefore, some cardiologists suggested that patients should discontinue ACEIs/ARBs to avoid the potential increased risk of SARS‐CoV‐2 infection.9 However, there is evidence demonstrating that the activation of the renin‐angiotensin system (RAS) and the downregulation of ACE2 expression are involved in the pathological process of lung injury after SARS‐CoV infection.10 Recently, it has been reported that serum level of angiotensin II is significantly elevated in COVID‐19 patients and exhibits a linear positive correlation to viral load and lung injury.11 Activation of the RAS can cause widespread endothelial dysfunction and varying degrees of multiple organ (heart, kidney, and lung) injuries. Thus, intake of ACEIs/ARBs might probably relieve the lung injury and absolutely decrease heart and renal damage resulting from the RAS activation. These possibilities pose a dilemma for the cardiologists in terms of recommending whether to discontinue ACEIs/ARBs or not. On the basis of the current literature, a viewpoint on the potential influence of ACEIs/ARBs on the onset and severity of SARS‐CoV‐2 infection is proposed in this article
    Keywords COVID-19 ; ACEI/ARB ; SARS‐CoV‐2 ; cardiovascular disease ; angiotensin‐converting enzyme 2
    Language English
    Document type Article
    Database Repository for Life Sciences

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top